
    
      This is a multi-site study to evaluate the safety and pharmacokinetics of repeated doses of
      IV SHR0410 in participants who are undergoing hemodialysis. Twenty-four eligible participants
      will be enrolled into 3 dose cohorts. SHR0410 will be administered after dialysis session.
      Safety assessments, PK assessments and efficacy evaluations will be performed.
    
  